Viewing Study NCT00233077



Ignite Creation Date: 2024-05-05 @ 12:04 PM
Last Modification Date: 2024-10-26 @ 9:19 AM
Study NCT ID: NCT00233077
Status: COMPLETED
Last Update Posted: 2013-12-03
First Post: 2005-10-03

Brief Title: Patient Centered Randomized Controlled Trial
Sponsor: Icahn School of Medicine at Mount Sinai
Organization: Icahn School of Medicine at Mount Sinai

Study Overview

Official Title: Patient Assistance to Reduce Breast Cancer Disparities
Status: COMPLETED
Status Verified Date: 2013-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to determine whether patient-assistance programs as compared with usual care will help women with early stage breast cancer receive appropriate treatments
Detailed Description: Numerous trials proved the efficacy of radiation following breast conserving surgery and systemic therapies to increase disease-free and overall survival among women with early-stage breast cancer Yet 14-89 of women do not receive them especially minority women Despite lower incidence of the disease African American women are more likely than white women to die of breast cancer As we near racial equity in rates of breast cancer screening disparities in treatment and mortality remain Efforts to achieve control of breast cancer and reduce racial disparities in mortality will not be fully realized until proven effective treatments are provided to those who can benefit

Underuse of effective treatments may be caused by patient physician and system factors For breast cancer screening womens lack of access to care insurance transportation beliefs about fatalism and curability and cancers effect on partner relationships all impact mammography rates For breast cancer treatment little is known about patient-related reasons for underuse and less is known about racial differences in such reasons

Interventions targeted to specific causes are more likely to succeed For breast cancer screening patient-centered interventions that successfully raise mammography rates among minority women include lay health workers to raise awareness about and address cultural beliefs and barriers to screening vouchers to pay for screening and navigators to help women with abnormal screenings obtain needed follow-up For breast cancer treatment patient-assistance programs provide practical support such as financial counseling aid with navigating the complex healthcare system emotional support and information about cancer and its treatment Such programs abound but patients are often unaware of them While these services may increase the receipt of effective adjuvant therapies these strategies have not been rigorously tested

We propose to conduct a randomized controlled trial to evaluate the effectiveness of patient-assistance programs as compared with usual care on receipt of adjuvant therapies among minority and nonminority women with newly operated early-stage breast cancer During the 24 month trial we will assess patients beliefs about cancer and its treatment and their practical psychosocial and informational needs and barriers to care We will identify and train employees in existing cancer assistance services in order to increase the sustainability of this program beyond the grant-funded cycle Specifically we propose

1 To assess racial differences in early-stage breast cancer patients experiences beliefs about and barriers to effective adjuvant treatments
2 To evaluate the effectiveness of an intervention connecting women with early-stage breast cancer and cancer-related needs to community and hospital-based patient-assistance programs to reduce underuse of effective adjuvant breast cancer treatment overall and in minority populations and to assess its sustainability and
3 To evaluate whether this patient assistance intervention affects patients knowledge attitudes and behaviors

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
1R01CA10705-01A1 OTHER_GRANT NCI None